

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61L 27/00		A1	(11) International Publication Number: WO 95/17217 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/SE94/01225		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
(22) International Filing Date: 19 December 1994 (19.12.94)			
(30) Priority Data: 9304209-1 20 December 1993 (20.12.93) SE 9401928-8 3 June 1994 (03.06.94) SE			
(71) Applicant (<i>for all designated States except US</i>): ASTRA AKTIEBOLAG (SE/SE); S-151 85 Söderälfje (SE).		Published <i>With international search report.</i>	
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): ELLINGSEN, Jan, Eirik [NO/NO]; Ekeberglia 14, N-1340 Bekkestua (NO). RØLLA, Gunnar [NO/NO]; Bygdey Allé 56A, N-0265 Oslo (NO).			
(74) Common Representative: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Söderälfje (SE).			
(54) Title: METALLIC IMPLANT AND PROCESS FOR TREATING A METALLIC IMPLANT			
(57) Abstract <p>A process for treating a metallic implant comprises treating the metallic implant with a solution of hydrofluoric acid of concentration up to 3 %.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Metallic implant and process for treating a metallic implant

5 Technical field of the invention.

The present application relates to biocompatible metallic bone implants, preferably made of titanium or an alloy thereof, and to a method for treating metallic implants
10 to enhance their biocompatibility.

Background to the invention.

A commonly used method for implanting metallic implants
15 into bone tissue is a two stage procedure involving in a first operation surgically placing the implant into the bone tissue, where it is then allowed to rest unloaded and immobile for a healing period of three months or more in order to allow the bone tissue to grow onto the
20 implant surface so as to permit the implant to be well attached to the bone tissue, the cut in the soft tissue covering the implant site being allowed to heal over the implant, and in a second operation opening the soft tissue covering the implant and attaching the functional
25 parts to the implant. This two-stage procedure is often used in connection with dental implants, one reason being that it minimizes the risk of infection of the implant site from the oral cavity. In some orthopaedic applications the above two-stage surgery may not be
30 necessary since most orthopaedic implants do not penetrate the soft tissue. A prolonged healing period is however still considered necessary since any movements

of the implant in the weeks and months following surgery may endanger the final attachment of the implant to the bone tissue.

5 The above procedure is for instance described in Bränemark et al: "Osseointegrated Implants in the Treatment of the Edentulous Jaw, Experience from a 10-year period", Almquist & Wiksell International, Stockholm - Sweden.

10 However, the fact that the implant may not be loaded means that the functional parts of the implant may not be attached to the implant and/or used during the healing period of three months or more. In view of the discomfort 15 associated with this, it is desirable to minimize the time period necessary for the above-mentioned first stage and in some cases, for instance in certain orthopaedic applications, substantially dispense with said first stage and perform the entire implantation procedure in a 20 single operation.

An object of the present invention is to provide an implant with improved rate of bone tissue attachment such that the post-surgery healing period described above may 25 be reduced.

Some of the metals or alloys used for bone implants are capable of forming a strong bond with the bone tissue, a bond which may be as strong as the bone tissue per se, sometimes even stronger. The most notable example of this 30 kind of metallic implant material is titanium and alloys of titanium whose properties in this respect have been known since about 1950. This bond between the metal and

bone tissue has been termed "osseointegration" by Bränemark et al.

Although this bond between titanium and bone tissue is
5 comparatively strong, in some applications it is
desirable to enhance the bond between metal and bone
tissue.

There are to date several methods for treating implants
10 made of titanium in order to obtain a better attachment
of the implant. Some of these involve altering the
topography of the implant, for example by creating
relatively large irregularities on the implant surface in
order to obtain a better mechanical retention and to
15 increase the area of attachment, by for example plasma
spraying, blasting or etching. Although the retention
may be improved, the time necessary for the
osseointegration process may be longer since the bone
tissue would have to grow into the irregularities in the
20 surface.

Other methods involve altering of the chemical properties
of the implant surface. For example one such method
involves the application of a layer of ceramic material
25 such as hydroxyapatite to the implant surface, inter alia
in order to stimulate the regeneration of the bone
tissue. Ceramic coatings however may be brittle and may
flake or break off from the implant surface, which may in
turn lead to the ultimate failure of the implant.

30 US Patent No. 4,330,891 could perhaps be said to combine
each of the above, in that the provision of an element
with a micro-pitted surface which micro-pits are within

a certain diameter range, is said to effect improved properties as regards acceptance of the carrier element, and primarily improved durability of the healthy ingrowth of the element due to its biological quality.

5

A further object of the invention is to provide an implant forming a stronger bond with the bone tissue.

Short description of the inventive concept.

10

It has been found that the desired metallic implant may be obtained by treating a metallic surgical implant with an aqueous solution of hydrofluoric acid.

15 Short description of the appended drawings

Fig 1 is a diagram illustrating the pushout force as well as the fluorine and oxygen content of an implant surface treated with 0.2% HF as a function of the treatment time.

20

Fig 2 is a SEM photograph of an implant surface treated with 0.2% HF for 30 seconds, in a magnification of 10 000 times,

25 Fig 3 is the implant surface in Fig 2, in 52 000 times magnification,

Fig 4 is a SEM photograph of an implant, in 10 000 times magnification, having been treated with 0.2% HF for 90

30 seconds,

Fig 5 is the surface of Fig 4 in 52 000 times magnification.

Fig 6 is a SEM photograph of an untreated implant surface in 52 000 times magnification.

- 5 Figs 7 - 9 are diagrams illustrating the effects of different treatments by means of calcium precipitation tests.

10 The invention

Accordingly, in a first aspect the present invention provides a process for the treatment of a metallic implant comprising treating the metallic implant with an aqueous solution of hydrofluoric acid, which solution is of pH 1.6 to pH 3.

Alternatively stated in terms of concentration, the present invention provides a process for the treatment of a metallic implant comprising treating the metallic implant with an aqueous solution of hydrofluoric acid of concentration up to 3.0%.

Preferably the metallic implant is made of commercially pure titanium or an alloy of titanium. The implants may be standard, blasted or other.

Preferably, the concentration of hydrofluoric acid is 0.01% to 3.0% such as 0.1% to 2.0%. Most preferably the concentration of hydrofluoric acid is about 0.2% to about 2.0% especially 0.2% to 0.5% and most preferably about 0.2%.

The treatment of the present invention may be carried out for any suitable length of time. Preferably the treatment is carried out for at least 10 seconds such as 10 seconds to 6 hours, for example 10 seconds to 2 minutes such as 10s to 50s, or 30s, 60s, or 2 minutes.

5 The treatment may be carried out in any suitable manner, for example by immersing the implant in the treatment solution for a period of time, and with or without 10 agitation. Varying temperatures may be employed; parameters such as temperature and time may be selected according to the concentration of the treatment solution and the other process parameters. The treatment is conveniently carried out at standard pressure, but 15 elevated pressures may be used where desired. Preferably, treatment is carried out at around standard temperature and pressure.

In a preferred embodiment the present invention provides 20 a process for the treatment of a metallic implant comprising treating the metallic implant with a 0.1-2.0% aqueous solution of hydrofluoric acid at room temperature for a period of up to 3 minutes.

25 The treatment solution of the present invention may be simply prepared, by diluting concentrated HF with distilled water.

Prior to treatment, the implant material may be cleaned 30 by standard techniques such as are well known in the art.

After treatment, the implant material may be washed in distilled water and kept under sterile conditions.

Implants treated in accordance with the present invention show a strong contact with bone, as demonstrated in "push-out" tests described herein, and a high degree of
5 bone contact in the spongiosa cancellous region. New bone will form on the implant surface in the cancellous region and will more or less cover the implant in this area. Such a response is not observed in untreated control groups. The degree of bone contact indicates bone growth
10 in the spongiosa cancellous region.

The process specified therefore beneficially effects the surface of the implant so as to improve the biocompatibility (specifically the rate of bone tissue
15 attachment and strength or bonding) of the implant. While we do not wish to be limited to the expression of theories herein, the improved biocompatibility is thought to be due, at least in part, to fluoride being retained on the surface of the implant. As such, treatments other
20 than with hydrofluoric acid, which provide fluoride ions, could be expected to have some effect on the biocompatibility of metallic implants. Treatment with sodium fluoride is known from our prior application WO 94/13334. In a second aspect this invention therefore
25 provides a process for treating a metallic implant comprising treating the implant with an aqueous solution containing fluoride ions in a concentration of up to 3%, said aqueous solution being free of sodium and sodium ions. The preferred treatment parameters correspond to
30 those preferred in the hydrofluoric acid treatment described herein.

Preferably no significant etching of the implant surface occurs with the present treatment. Most preferably, there is substantially no etching of the implant surface.

5 Implants treated by the process of the present invention are also provided herein. Therefore in a third aspect the present invention provides a metallic implant which has been treated with an aqueous solution of hydrofluoric acid according to the processes described herein.

10 As stated hereinabove, the beneficial effect of the present invention is thought to be related to fluoride being retained on the surface of the treated implant. The treatment described is a surface treatment which 15 affects the surface properties of the implant although at this stage it is not possible to define the surface characteristics of the treated implant more than to say that the desired characteristics are provided by the present process.

20 In a fourth aspect therefore the present invention provides a metallic implant having a surface equivalent to the surface of an implant which has been treated with an aqueous solution of hydrofluoric acid according to the 25 processes described herein.

Another way of describing the effect of the present treatment is by means of the induction of calcium phosphate precipitation. This is an *in vitro* test described in 30 "Damen, Ten Cate, Ellingsen, Induction of Calcium Precipitation by Titanium Dioxide, Journal of Dental Research, October 1991". In this method an implant is immersed in a saturated solution of calcium phosphate.

- Depending on the surface, precipitation of calcium onto the implant occurs. The concentration of Ca⁺⁺ is monitored and the time delay (the induction time) until precipitation occurs is measured. The rationale behind this test is the
5 assumption that there is a correlation between the affinity of the implant surface towards the calcium ions and the biocompatibility of the implant surface in bone tissue. Implants treated in accordance with the present invention show an affinity to calcium ions in this test.
- 10 Accordingly, in a fourth aspect the present invention provides an implant treated with hydrofluoric acid in accordance with the present invention, which implant precipitates calcium ions from a saturated solution of calcium phosphate.

15

The following Examples illustrate the invention.

Examples

20 Example 1

Seven surgical implants, of commercially pure (c.p.) titanium, 5 mm in length and generally conical in shape having a diameter at one end of 3 mm and at the other end 2 mm, were prepared by machining using a "Maximat super 11"
25 (TM) turning lathe. Therefore the area of the conical sides of the implant, i.e. the part of the implant to be located in the bone, is 39 mm².

Each implant was cleaned according to a well-known cleaning procedure involving the following steps:

1. Treatment with trichloroethylene with ultrasonic treatment, for 15 minutes.

2. Rinsing in absoute ethanol, for 10 seconds.
 3. Three successive treatments with ethanol with ultrasonic treatment, each for 10 minutes.
- Each cleaned implant was sterile packaged in a Medioplast 5 (TM) sterile envelope, and autoclaved in a Citomat 162 (TM) (LIC Company) autoclave, at 120 C for 30 minutes.

A HF bath was prepared simply by diluting concentrated HF with distilled water, to give a 0.2% solution. The pH of 10 the bath was 2.1.

Seven implants, prepared, cleaned, sterile packaged and autoclaved exactly as described above, were removed from their sterile packages, placed in the HF treatment bath and 15 left there for two minutes. Thereafter each was washed three times in a bath of distilled water, for periods of 30 seconds each wash. After being allowed to dry at room temperature, each implant was transferred to a Medioplast (TM) sterile envelope to await surgical implantation.

20

Implant study

Chinchilla rabbits were used as test animals. The rabbits were randomly distributed regarding sex, but all had a 25 weight of 2.5 kg at the start of the study. Each animal was sedated by injection using a combination of fluanzonium 1.0 mg/kg and fentanyl 0.02 mg/kg (Hypnorm, Jannsen Pharmaceuticals, Belgium) and locally anesthetised with xylocaine/adrenaline (AB Astra). Two cavities were 30 drilled in each rabbit's right ulna, using standardised bores designed to provide cavities into which the conical implants would exactly fit. Treated and untreated implants were placed in the cavities of each rabbit, using titanium

tweezers so as to avoid the influence of other metals, and left for sixty days.

At the end of sixty days the rabbits were sacrificed by
5 injection with pentobarbitol sodium, and the ulna's removed and placed in sterile physiological saline to await a "push-out" test the same day.

An Instron model 1121 tensile testing machine (Instron, 10 U.K.) inter alia comprising a support jig and a ram adjusted for a load range of 0 - 200 N, was employed to measure the force needed to separate each implant from bone. Milling tracks, to fit the support jig, were made in the specimen to be tested, in the bone surrounding the 15 larger end of the implant, and the specimen was placed on the support jig. The ram was lowered at a speed of 1 mm/min., and the force required to separate the implant from the bone was recorded.

20 This recorded force gives a direct assessment of the strength of connection of the implant and bone, the higher the required force the stronger the connection.

The results are recorded in Table 1.

25

Table 1

Recorded force (N)

		Untreated implants	Treated implants
30	1	18.1	1 84.1
	2	59.2	2 96.0
	3	44.7	3 64.2
	4	39.2	4 62.7

5	59.5	5	64.9
6	6.0	6	89.5
7	8.5	7	89.5
mean 33.6		mean 78.7	

5

The much greater strength of bone connection with implants treated in accordance with the present invention is apparent from the above.

- 10 Histological examination demonstrated that the implants according to Example 1 were surrounded even in the ulna's spongiosa by a thick layer of newly formed bone which was in close contact with the implants. In contrast the untreated implants, i.e. those according to the Comparative Examples, were only partly covered, by a thin bone layer, in the spongiosal area.
- 15

Example 2.

- 20 Reference implants were made of titanium grade 3, and were made by turning at an average speed of about 7 meters per minute. No cutting fluid was used. The cutting tool was made of high speed steel.
- 25 The reference implant surface was cleaned by a standard cleaning procedure involving the following steps:
1. Treatment with trichloroethylene with ultrasonic treatment for 15 minutes.
 - 30 2. Rinsing in absolute ethanol for 10 seconds.

3. Three successive treatments with ethanol with ultrasonic treatment, each for 10 minutes. Each cleaned implant should then be sterile packaged in a Medioplast (TM) sterile envelope and autoclaved in a Citomat 162 (TM) (LIC Company) autoclave at 120 ° C for 30 minutes.

The result of an experiment in which the force necessary for removing (pushing out) substantially conical, unthreaded implants treated in 0.2% aqueous solution of hydrofluoric acid at room temperature for different time periods is illustrated in the diagram in Fig 1. The implants had been manufactured to have a diameter of 2 mm at one end, 3 mm at the other end and an overall length of 5 mm and were made from titanium grade 3 and cleaned and sterilized in accordance with the above procedures for treating the reference implant surface. The treatment times were 10 seconds, 30 seconds, 60 seconds, 90 seconds, 120 seconds and 180 seconds. Pushout tests were made and the pushout forces were marked in the diagram for each treatment time except 90 and 180 seconds. The values for an untreated control specimen are also given in the diagram as having a treatment time of 0 seconds.

Each value for the pushout test results are a mean of the values for four implants implanted in the tibia of a respective rabbit and left to heal into the bone tissue for two months.

The reference implants were also treated in the way described above. The content of flourine and of oxygen as measured in the surface of the treated implants are marked in the diagram for each treatment time.

An Instron model 1121 tensile testing machine (Instron, U.K.) set to the same parameters as the machine in Example 1 was used and the contents of fluorine and oxygen were measured by means of an Electron microprobe (CAMECA 5 camebax) at SINTEF/SI in Oslo. The results as measured with this equipment were

	F%	O%
0 sec	0.01	5.1
10 sec	0.15	5.5
10 30 sec	0.11	5.8
60 sec	0.17	5.7
90 sec	0.2	9.4
120 sec	0.23	8.4
180 sec	0.16	11.0

15 The diagram in Fig 1 illustrates higher values for the pushout tests resulting from treatment times varying between 10 and 50 seconds with a peak value at 30 seconds. The values for the remaining treatment times and the 20 untreated control specimens are lower although the treated implants generally have higher values than the untreated ones. The values for the oxygen (5.5 to 5.8%) and fluorine content (0.11 to about 0.15%) of the surface of the implants for the treatment times between 10 and 50 seconds 25 are lower than the corresponding values for the other treatment times.

The pushout tests were made after a time period which was as short as two months. The rapid increase of the strength 30 of the bond results in that the healing period necessary for reaching a given strength of the bone is shortened. The use of the treatment according to the invention thus facilitates the use of one-stage surgical procedures,

particularly in orthopaedics, since the time the patient must remain inactive is shortened.

- Fig 2 illustrates how the implant surface seems to be largely unaffected by the treatment involving a HF-5 concentration of 0.2% and a treatment time of 30 sec, no effect being discernable in a magnification of 10 000 times (the original tooling marks not being affected at all). This photograph should be compared with the photograph in Fig 4, in 10 000 times magnification, showing a surface which has been treated longer (90 seconds) in 0.2% HF and in which the marked change in the surface by the treatment in question is illustrated.
- 15 Fig 3, which shows the surface in Fig 2 in a magnification of 52 000 times, should be compared with Fig 6, which shows an untreated surface in a magnification of 52 000 times, and with Fig 5, which shows the surface of Fig 4 in a magnification of 52 000 times. As is evident, the surface 20 treated with 0.2% solution is only slightly affected in regard of the morphology, the tooling marks still being discernable, whereas the surface treated for a longer period of time is distinctly altered and covered with a porous layer. It is believed that the best embodiment of 25 the invention involves surfaces whose morphology only are slightly affected by the treatment although other treated surfaces also may have the effect expected from the invention.
- 30 In the above push out test implants manufactured and treated in the same way as the reference implant surface were used. It should however be noted that the metallic implants to be used in the clinical situation and/or in

research of course can be manufactured of any metal and treated in any way within the scope of the claims provided the implant surface is equivalent to the reference surface in regard of the content of fluorine.

5

Example 3.

Another way of describing the effect of the treatment is by means of the induction of Calcium Phosphate Precipitation.

- 10 This is an in vitro test described in "Damen, Ten Cate, Ellingsen, Induction of Calcium Precipitation by Titanium Dioxide, Journal of Dental Research, October 1991". In this method an implant is immersed in a saturated solution of calcium phosphate. Depending on the surface, precipitation 15 of calcium onto the implant occurs. The concentration of Ca^{++} is monitored and the time delay (the induction time) until precipitation occurs is measured. The rationale behind this test is the assumption that there is a correlation between the affinity of the implant surface 20 towards the calcium ions and the biocompatibility of the implant surface in bone tissue. The results of the tests are illustrated in the appended diagrams, Figs 7 - 10. The concentration of Ca^{++} is given on the Y-axis ($2.00\text{e}-1$ means 2.00×10^{-1} etc). The test time is given on the X-axis 25 in minutes.

The implants in the test had been treated as follows:

Concentration, HF Treatment time

0.05 %	180 sec
30 0.15 %	180 sec
0.2 %	30, 60, 120 sec
0.5 %	60 sec
2.0 %	60 sec

Untreated control implants were also tested.

The test solution was a solution comprising 7.5 mM KH₂PO₄, and 50 mM HEPES (pH 7.2) added to a solution comprising 1
5 mM CaCl₂, and 50 mM HEPES (pH 7.2). HEPES is a standard buffering solution. The temperature of the solution during the tests was 37 degrees centigrade.

The concentration of the calcium in the solution after
10 immersion of the respective implant is measured at a calcium selective electrode during a time period of 5 hours. As indicated in the diagrams, there is no precipitation in solutions in which the control implants and implants treated with 0.15% HF have been immersed
15 during the 5 hour immersion time, see fig 7.

For certain of the implants treated with 0.2 % HF there was precipitation in the test solution as early as 4 hours after the immersion. These implants had been
20 treated with HF for 60 and 120 sec. Implants having been treated with 0.2% HF for 30 sec caused precipitation, but not until about 5 hours immersion time, see fig 8.

Implants treated with 0.5 % HF for 60 sec caused
25 precipitation at about 4 hour immersion time, whereas the implants treated with 2.0% HF for 60 sec caused precipitation both before and after 5 hour immersion time.

30 According to these data there would seem to be ranges of HF concentrations and treatment times giving the desired result, with a central range around 0.2 - 0.5 % giving better results. These data to some extent complement the

data in the previous examples, and it consequently is believed that the implants according to the invention also can be defined by means of this test, which is a relatively simple one.

5

Accordingly, an implant according to the invention can be defined as an implant having been treated with HF and which causes precipitation of calcium ions onto the implant surface from a solution comprising 7.5 mM KH_2PO_4 , 10 and 50 mM HEPES (pH 7.2) added to a solution comprising 1 mM CaCl_2 and 50 mM HEPES (pH 7.2), the temperature of the solution during the tests being 37 degrees centigrade.

15 Example 4

Screwshaped implants having been implanted into bone tissue in the ulna of rabbits for 2 months were removed by torque and histological studies of the implant surface 20 were made.

For a standard implant treated in 0.2 % HF for 120 sec, the bone contact was 63.3%, whereas the bone contact for a standard, untreated control implant was only 42.4 %.

25

For an implant blasted with particles of titanium dioxide and treated in 0.2 % HF for 90 sec the bone contact was 53.5% whereas the bone contact for a similarly blasted, but untreated implant was 37.3%.

30

The above values are mean values for 4 - 8 implants.

The bone contact was more pronounced in the spongiosa for
the treated implants.

The treated implants consequently show a pronounced
5 improvement in comparison with the untreated implants.

Claims

1. A process for treating a metallic implant comprising
treating the metallic implant with a solution of
5 hydrofluoric acid, which solution is of pH 1.6 to 3.0.
2. A process for treating a metallic implant comprising
treating the metallic implant with a solution of
hydrofluoric acid of concentration up to 3%.
- 10 3. A process as claimed in claim 2 in which the
concentration of hydrofluoric acid is 0.1% to 2.0%.
- 15 4. A process as claimed in claim 2 in which the
concentration of hydrofluoric acid is 0.2% to 2.0%.
5. A process as claimed in claim 2 in which the
concentration of hydrofluoric acid is approximately 0.2%.
- 20 6. A process as claimed in claim 1 or 2 in which the
treatment is carried out for a period of at least 10
seconds.
- 25 7. A process as claimed in claim 6 in which the treatment
is carried out for a period of 10 seconds to 2 minutes.
8. A process for treating a metallic implant comprising
treating the metallic implant with a solution of
hydrofluoric acid of concentration 0.1% to 2.0% aqueous
30 solution of hydrofluoric acid at room temperature for a
period of up to 3 minutes.

9. A process as claimed in claim 8 in which the concentration of hydrofluoric acid is 0.2% to 2.0%.
10. Implant obtainable by the process of any of the claims
5 1 - 9.
11. A process for treating a metallic implant, comprising treating the metallic implant with an aqueous solution containing fluoride ions in a concentration of up to 3%,
10 said aqueous solution being free of sodium and sodium ions.
12. A metallic implant treated according to a process as claimed in claim 1, 2 or 8.
- 15 13. A metallic implant treated according to the process claimed in claim 10.
14. A metallic implant having a surface equivalent to that of the implant claimed in claim 11.
20
15. A metallic implant as claimed in claim 11, which implant precipitates calcium ions from a saturated solution of calcium phosphate.
- 25 16. A metallic implant having been treated with HF, which implant causes precipitation of calcium ions onto the implant surface from a solution comprising 7.5 mM KH₂PO₄ and 50 mM HEPES (pH 7.2) added to a solution comprising 1 mM CaCl₂ and 50 mM HEPES (pH 7.2), the temperature of the
30 solution during the tests being 37 degrees centigrade, the duration of the test being 5 hours.

17. A metallic implant according to claim 16, in which said duration of said test is 4 hours.

18. Metallic implant for implantation in bone tissue,
5 characterized in that the surface of said metallic implant contains fluorine and/or fluoride ions in an amount equivalent to that obtained by means of treatment of a reference implant surface with a 0.2% aqueous solution of hydrofluoric acid at room temperature
10 for 10 - 50 seconds.

19. Metallic implant according to claim 18,
characterized in that said metallic implant is made of commercially pure titanium or an alloy of
15 titanium.

20. Metallic implant according to claim 19,
characterized in that the surface of said metallic implants contains fluorine and/or fluoride ions in an amount equivalent to that obtained by means of a treatment with a 0.2% aqueous solution of hydrofluoric acid at room temperature for 30 seconds.

1/6




FIG 1. The relation between the concentration of F and O on the titanium surface and the biological effect as measured by push out technique.

275



1 μm 22.7 kV 1.00E4 2567/00 SE

FIG 2.



1 μm 20.4 kV 5.20E4 0.040/00 SE

FIG 3.

SUBSTITUTE SHEET

BEST AVAILABLE COPY

3/6




FIG 4.



FIG 5.

SUBSTITUTE SHEET BEST AVAILABLE COPY

4 / 6



FIG 6.

5/6




FIG. 7




FIG. 8

SUBSTITUTE SHEET

6/6




FIG. 9

INTERNATIONAL SEARCH REPORT

1

International application No.

PCT/SE 94/01225

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61L 27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61L, A61F, A61C, C23F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, EPODOC, PAJ, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO, A1, 9413334 (AKTIEBOLAGET ASTRA), 23 June 1994 (23.06.94) --	1-20
X	EPOQUE, PAJ/JPO, JP3146679, HARUYUKI KAWAHARA: "LIVING BODY-RESTORING MEMBER MADE OF TITANIUM OR TITANIUM ALLOY AND ITS SURFACE TREATMENT", 910621 --	1-14
A	EP, A1, 0388576 (INSTITUT STRAUmann AG), 26 Sept 1990 (26.09.90), page 2, line 30 - line 33, claims 2, 6 --	1

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document published on or after the international filing date
- "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be anticipated or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be anticipated or involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

27 March 1995

31.03.95

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer

Sofia Nikolopoulou
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/SE 94/01225

25/02/95

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A1- 9413334	23/06/94	NONE		
EP-A1- 0388576	26/09/90	SE-T3- 0388576 DE-D- 58905636 ES-T- 2044211 JP-A- 3047264		00/00/00 01/01/94 28/02/91